Human CD55 / DAF Protein, His Tag

Proteins and Peptides

貨號 Cat. No.
CD5-H5225
規格 Size
100ug
品牌 Brand
ACROBiosystems
Species
Human
Conjugate
Unconjugated
Expression System
HEK293
Tag
His Tag

Description




Source : 


Human CD55, His Tag (CD5-H5225) is expressed from human 293 cells (HEK293). It contains AA Asp 35 - Ser 353 (Accession # NP_000565.1).


 

Molecule : CD55


 

Synonyms : CD55,DAF,CR,CROM,TC


 

Format : Powder


 

Category : Bio-Markers & CD Antigens


 

Accession : NP_000565.1


 

Storage : -20℃


 

Shipping condition : Powder,RT


 

Molecular Weight : 35.8 kDa


 

Characteristics :


This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 35.8 kDa. The protein migrates as 50-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.


 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.


 

Buffer : PBS, pH7.4


 

Description :


CD55 is also known as DAF or decay­accelerating factor, is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. CD55 /DAF is a 70 kDa membrane protein that regulates the complement system on the cell surface. It prevents the assembly of the C3bBb complex (the C3-convertase of the alternative pathway) or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex. This glycoprotein is broadly distributed among hematopoietic and non-hematopoietic cells. It is a determinant for the Cromer blood group system. CD55 is known to bind CD97 via the first SCR. It also binds physiologically­generated C3 convertases with its second and third SCRs. Binding results in an accelerated “decay”, or dissociation of active C3 convertases, thus blocking the development of C’ attack complexes on nonforeign cells. Finally, viruses and bacteria are also known to utilize multiple SCR sites for infection.


 

References :


(1) Medof ME, et al., 1987, Proc. Natl. Acad. Sci. U.S.A. 84 (7): 2007–11.
(2) Karnauchow TM, et al., 1996, J. Virol. 70 (8): 5143–52.
(3) Spiller OB, et al., 2000, J. Infect. Dis. 181 (1): 340–3.
(4) Williams, P. et al., 2003, J. Biol. Chem. 278:10691.
(5) Lea, S., 2002, Biochem. Soc. Trans. 30:1014. 





詢價 / 洽詢此產品

同品牌其他產品

回到產品列表

▲ LINE
諮詢